DNA X Valuation Multiples

Discover revenue and EBITDA valuation multiples for DNA X and similar public comparables like AGM Group Holdings, Cambium Networks, Boxlight, Weaccess Group and more.

DNA X Overview

About DNA X

DNA X Inc operates a digital asset management platform.


Founded

1999

HQ

United States

Employees

160

Financials (FY)

Revenue: -
EBITDA: ($2M)

EV

$5M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

DNA X Financials

DNA X reported last fiscal year revenue of - and negative EBITDA of ($2M).

In the same fiscal year, DNA X generated - in gross profit, ($2M) in EBITDA losses, and had net loss of ($21M).


DNA X P&L

In the most recent fiscal year, DNA X reported revenue of - and EBITDA of ($2M).

DNA X is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.

See analyst estimates for DNA X
LTMLast FY202320242025202620272028
Revenue--$94M$58M-
Gross Profit--$19M$10M-
Gross Margin--21%17%-
EBITDA-($2M)$3M($30M)($2M)
EBITDA Margin--3%(51%)-
EBIT Margin--1%(51%)-
Net Profit($21M)($21M)($90K)($34M)($21M)
Net Margin--(0%)(58%)-
Net Debt-$4M---

Financial data powered by Morningstar, Inc.

DNA X Stock Performance

DNA X has current market cap of $5M, and enterprise value of $5M.


DNA X's stock price is $3.39.

DNA X has an EPS (earnings per share) of $-13.88.

See more trading valuation data for DNA X
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$5M$5M-4.8%---$-13.88

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

DNA X Valuation Multiples

DNA X trades at (2.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for DNA X

DNA X Financial Valuation Multiples

As of August 15, 2026, DNA X has market cap of $5M and EV of $5M.

DNA X has a P/E ratio of (0.2x).

LTMLast FY202320242025202620272028
EV/Revenue--0.1x0.1x-
EV/EBITDA-(2.3x)2.0x(0.2x)(2.3x)
EV/EBIT-(0.9x)9.6x(0.2x)(0.9x)
EV/Gross Profit--0.3x0.5x-
P/E(0.2x)(0.2x)(56.1x)(0.1x)(0.2x)
EV/FCF-(0.2x)(1.2x)(0.6x)(0.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified DNA X Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

DNA X Margins & Growth Rates

See estimated margins and future growth rates for DNA X

DNA X Margins

2024202720282029
Gross Margin17%
EBITDA Margin(51%)
EBIT Margin(51%)
Net Margin(58%)
FCF Margin(15%)

DNA X Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(38%)(100%)
Gross Profit Growth(49%)(100%)
EBITDA Growth(1291%)(93%)
EBIT Growth(5882%)(82%)
Net Profit Growth37287%(39%)
FCF Growth113%170%

Data powered by FactSet, Inc. and Morningstar, Inc.

DNA X Operational KPIs

DNA X's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for DNA X
Last FY20232024202620272028
Revenue per Employee$0.0M--
Opex per Employee$0.0M--
S&M Expenses to Revenue-9%22%
G&A Expenses to Revenue-9%21%
R&D Expenses to Revenue-2%24%
Opex to Revenue-20%68%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
AGM Group Holdings0.2x-(1.4x)-
Cambium Networks0.5x-(3.2x)-
Boxlight0.4x0.4x(8.8x)-
Weaccess Group4.5x-17.4x-
Adeunis RF1.1x-(2.5x)-
Telgam2.5x-11.2x-
Maxcom0.2x-21.3x-
Indeco----

This data is available for Pro users. Sign up to see all DNA X competitors and their valuation data.

Start Free Trial

DNA X VC Funding History

Before going public, DNA X raised $35M in total equity funding, across 2 rounds.


DNA X Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-18Series A-$8M-Sonim Technologies, a San Diego-based telecommunications company specializing in rugged mobile phones, reported annual revenue of $58.3 million. Total funding across rounds amounted to $21 million.
Dec-17Undisclosed stageB. Riley Financial$27M-Sonim Technologies, a maker of rugged cell phones, raised $37 million in financing from B. Riley Financial in December 2017, consisting of $27 million in equity capital and $10 million in subordinated debt through a revolving credit facility. B. Riley FBR served as financial advisor, while B. Riley Principal Investments acted as lead investor, syndicating the equity and providing the debt. The funds supported growth initiatives, including ruggedized IoT and advanced AI capabilities for Fortune 1000 industrial companies and public safety sectors. The company focused on public safety and security markets projected to grow significantly.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About DNA X

When was DNA X founded?DNA X was founded in 1999.
Where is DNA X headquartered?DNA X is headquartered in United States.
How many employees does DNA X have?As of today, DNA X has over 160 employees.
Is DNA X publicly listed?Yes, DNA X is a public company listed on Nasdaq.
What is the stock symbol of DNA X?DNA X trades under SONM ticker.
When did DNA X go public?DNA X went public in 2019.
Who are competitors of DNA X?DNA X main competitors include AGM Group Holdings, Cambium Networks, Boxlight, Weaccess Group, Adeunis RF, Telgam, Maxcom, Indeco, Realfiction, Vislink Technologies.
What is the current market cap of DNA X?DNA X's current market cap is $5M.
Is DNA X profitable?No, DNA X is not profitable.
What is the current net income of DNA X?DNA X's last 12 months net income is ($21M).
How many companies DNA X has acquired to date?DNA X hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies DNA X has invested to date?DNA X hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to DNA X

Lists including DNA X

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial